NASDAQ
20.54USD
-0.66 (-3.11%)
We have scored 11 news catalysts on MiniMed Group, Inc. Common Stock (MMED) over the past 12 months. The biggest single-day move next to one of them came Jun 3, 2026, when MMED closed +15.9%: “MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott”. Coverage across the window leans positive (average ticker sentiment +0.70). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.8B
P/E
—
EPS
—
Beta
-3.71
52W range
10.65-24.43
Day range
20.37–21.26
Open
21.17
Prev close
21.20
Volume
2.8M
Avg volume
1.4M
Dividend
0.00
IPO
2026-03-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MiniMed Group, Inc. Common Stock — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of MiniMed Group, Inc. Common Stock, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MMED: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
